Earnings Call

The ticket marketplace saw revenue fall year-over-year, but a surge in cash flow and sequential growth offers a potential path to recovery.

As Sachem Capital sets its Q1 earnings date, investors watch closely for signs of stability in the hard money lending market after a volatile period.

Aon reports a robust start to 2026 with 5% organic growth and a 332% jump in free cash flow, underscoring the success of its integrated strategy.

MPS smashes Q1 revenue records, fueled by a 98% surge in its AI data segment. The company now eyes a massive $6 billion capacity expansion.

Activist investor Trian Fund Management launches a public campaign against Solventum, alleging massive value destruction and excessive executive compensation.

Pursuit will release its Q1 2026 results on May 6. The report will test its strategy and offer a key health check for the global tourism sector.

Philip Morris International's upcoming Q1 2026 earnings will be a crucial test of its pivot from cigarettes, with all eyes on ZYN's growth and regulatory hurdles.

As TI preps its Q1 2026 earnings call, all eyes are on its performance as an indicator for the industrial, auto, and broader semiconductor sectors.

As Milestone Scientific prepares its year-end call, investors look for signs of a turnaround and growth for its advanced injection technology.

The midstream firm is refinancing debt and buying back preferred units, aiming for a simpler, more flexible financial future. What does this mean for NGL?

After a 39% stock crash, Lakeland Industries' former CFO is sued over allegedly misleading investors about the company's deteriorating financial health.

FinVolution Group is set to release its 2025 financials, with investors watching to see if international growth and AI tech can navigate market headwinds.

Fresh off a blockbuster IPO, SpyGlass Pharma heads to a key investor summit. Can its revolutionary long-acting drug platform transform chronic eye care?

The spirits giant faces a steep sales decline and a massive write-down, pivoting to premium brands and operational fixes amid an industry-wide hangover.

Beam Therapeutics is set to announce its 2025 financial results and a new liver-targeted therapy, a key moment for its base editing platform and investors.

With a novel skin drug launched, Pelthos Therapeutics heads to a key conference. Can its focused strategy convince Wall Street of its blockbuster potential?

As VerticalScope preps its 2025 results, investors watch if its pivot to AI and e-commerce can overcome ad market and search engine challenges.

Compass Diversified sets its earnings date, putting its post-Lugano strategy and portfolio health under intense scrutiny from investors.

With COVID revenue fading, QuidelOrtho will use a key conference to prove its diversified diagnostics model can deliver on growth, margins, and cash flow.

As BJ’s prepares to report Q4 results, investors are watching if a pizza relaunch and new efficiencies can overcome industry-wide cost pressures.